RAS mutation associated with short surgically controllable period in colorectal liver metastases: a retrospective study.
Colorectal cancer
Liver metastasis
Neoadjuvant chemotherapy
RAS
Surgically controllable period
Journal
World journal of surgical oncology
ISSN: 1477-7819
Titre abrégé: World J Surg Oncol
Pays: England
ID NLM: 101170544
Informations de publication
Date de publication:
12 Sep 2024
12 Sep 2024
Historique:
received:
16
06
2024
accepted:
03
09
2024
medline:
13
9
2024
pubmed:
13
9
2024
entrez:
12
9
2024
Statut:
epublish
Résumé
The prognostic implications of the RAS status in colorectal cancer liver metastasis (CRLM) remain unclear. This study investigated the prognostic significance of RAS status after curative hepatectomy, focusing on surgical controllability. This retrospective study included liver-only CRLM patients who underwent the first hepatectomy between 2015 and 2022 at the National Cancer Center Hospital. Recurrence-free survival (RFS), surgically controllable period (SCP), and overall survival (OS) were compared between RAS wild-type (RAS-wt) and mutant (RAS-mt) patients. Multivariate analyses were conducted to identify independent prognostic factors for each outcome and independent risk factors for less than 1 year SCP. A total of 150 patients were evaluated, comprising 63 patients with RAS-mt status. There was no significant difference in RFS between RAS-mt and RAS-wt (7.00 vs. 8.03 months, p = 0.48). RAS-mt patients exhibited worse SCP (11.80 vs.21.13 months, p < 0.001) and OS (44.03 vs. 70.03 months, p < 0.001) compared to RAS-wt. Multivariate analysis identified RAS-mt as an independent prognostic factor for both OS (hazard ratio [HR]: 3.37, p < 0.001) and SCP (HR: 2.20, p < 0.001), and as an independent risk factor for less than 1 year of SCP (odds ratio, 2.31; p = 0.03). CRLM with RAS mutations should be considered for strict surgical indications with preoperative chemotherapy and thorough examination, considering the possibility of short SCP.
Sections du résumé
BACKGROUND
BACKGROUND
The prognostic implications of the RAS status in colorectal cancer liver metastasis (CRLM) remain unclear. This study investigated the prognostic significance of RAS status after curative hepatectomy, focusing on surgical controllability.
METHODS
METHODS
This retrospective study included liver-only CRLM patients who underwent the first hepatectomy between 2015 and 2022 at the National Cancer Center Hospital. Recurrence-free survival (RFS), surgically controllable period (SCP), and overall survival (OS) were compared between RAS wild-type (RAS-wt) and mutant (RAS-mt) patients. Multivariate analyses were conducted to identify independent prognostic factors for each outcome and independent risk factors for less than 1 year SCP.
RESULTS
RESULTS
A total of 150 patients were evaluated, comprising 63 patients with RAS-mt status. There was no significant difference in RFS between RAS-mt and RAS-wt (7.00 vs. 8.03 months, p = 0.48). RAS-mt patients exhibited worse SCP (11.80 vs.21.13 months, p < 0.001) and OS (44.03 vs. 70.03 months, p < 0.001) compared to RAS-wt. Multivariate analysis identified RAS-mt as an independent prognostic factor for both OS (hazard ratio [HR]: 3.37, p < 0.001) and SCP (HR: 2.20, p < 0.001), and as an independent risk factor for less than 1 year of SCP (odds ratio, 2.31; p = 0.03).
CONCLUSIONS
CONCLUSIONS
CRLM with RAS mutations should be considered for strict surgical indications with preoperative chemotherapy and thorough examination, considering the possibility of short SCP.
Identifiants
pubmed: 39267117
doi: 10.1186/s12957-024-03529-9
pii: 10.1186/s12957-024-03529-9
doi:
Substances chimiques
Biomarkers, Tumor
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
247Informations de copyright
© 2024. The Author(s).
Références
The Editorial Board of the Cancer Statistics in Japan. CANCER STATISTICS IN JAPAN. 2024. Tokyo: Foundation for Promotion of Cancer Research, 2024: 14–25.
Bray F, Laversanne M, Sung H, Ferlay J, Siegel RL, Soerjomataram I, Jemal A. Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2024;74:229–63.
doi: 10.3322/caac.21834
pubmed: 38572751
Leporrier J, Maurel J, Chiche L, Bara S, Segol P, Launoy G. A population-based study of the incidence, management and prognosis of hepatic metastases from colorectal cancer. Br J Surg. 2006;93:465–74.
doi: 10.1002/bjs.5278
pubmed: 16523446
Yamazaki K, Nagase M, Tamagawa H, Ueda S, Tamura T, Murata K, Eguchi Nakajima T, Baba E, Tsuda M, Moriwaki T, et al. Randomized phase III study of bevacizumab plus FOLFIRI and bevacizumab plus mFOLFOX6 as first-line treatment for patients with metastatic colorectal cancer (WJOG4407G). Ann Oncol. 2016;27:1539–46.
doi: 10.1093/annonc/mdw206
pubmed: 27177863
Loupakis F, Cremolini C, Masi G, Lonardi S, Zagonel V, Salvatore L, Cortesi E, Tomasello G, Ronzoni M, Spadi R, et al. Initial therapy with FOLFOXIRI and bevacizumab for metastatic colorectal cancer. N Engl J Med. 2014;371:1609–18.
doi: 10.1056/NEJMoa1403108
pubmed: 25337750
Simmonds PC, Primrose JN, Colquitt JL, Garden OJ, Poston GJ, Rees M. Surgical resection of hepatic metastases from colorectal cancer: a systematic review of published studies. Br J Cancer. 2006;94:982–99.
doi: 10.1038/sj.bjc.6603033
pubmed: 16538219
pmcid: 2361241
Minagawa M, Makuuchi M, Torzilli G, Takayama T, Kawasaki S, Kosuge T, Yamamoto J, Imamura H. Extension of the frontiers of surgical indications in the treatment of liver metastases from colorectal cancer: long-term results. Ann Surg. 2000;231:487–99.
doi: 10.1097/00000658-200004000-00006
pubmed: 10749608
pmcid: 1421023
Adam R, Pascal G, Azoulay D, Tanaka K, Castaing D, Bismuth H. Liver resection for colorectal metastases: the third hepatectomy. Ann Surg. 2003;238:871–83. discussion 883 – 874.
doi: 10.1097/01.sla.0000098112.04758.4e
pubmed: 14631224
pmcid: 1356169
Yan TD, Sim J, Black D, Niu R, Morris DL. Systematic review on safety and efficacy of repeat hepatectomy for recurrent liver metastases from colorectal carcinoma. Ann Surg Oncol. 2007;14:2069–77.
doi: 10.1245/s10434-007-9388-6
pubmed: 17440785
Bond MJG, Bolhuis K, Loosveld OJL, de Groot JWB, Droogendijk H, Helgason HH, Hendriks MP, Klaase JM, Kazemier G, Liem MSL, et al. First-line systemic treatment strategies in patients with initially unresectable colorectal cancer liver metastases (CAIRO5): an open-label, multicentre, randomised, controlled, phase 3 study from the Dutch Colorectal Cancer Group. Lancet Oncol. 2023;24:757–71.
doi: 10.1016/S1470-2045(23)00219-X
pubmed: 37329889
Su YM, Liu W, Yan XL, Wang LJ, Liu M, Wang HW, Jin KM, Bao Q, Wang K, Li J, et al. Five-year survival post hepatectomy for colorectal liver metastases in a real-world Chinese cohort: recurrence patterns and prediction for potential cure. Cancer Med. 2023;12:9559–69.
doi: 10.1002/cam4.5732
pubmed: 36846977
pmcid: 10166917
Beppu T, Sakamoto Y, Hasegawa K, Honda G, Tanaka K, Kotera Y, Nitta H, Yoshidome H, Hatano E, Ueno M, et al. A nomogram predicting disease-free survival in patients with colorectal liver metastases treated with hepatic resection: multicenter data collection as a project study for hepatic surgery of the Japanese society of Hepato-biliary-pancreatic surgery. J Hepatobiliary Pancreat Sci. 2012;19:72–84.
doi: 10.1007/s00534-011-0460-z
pubmed: 22020927
Beppu T, Yamamura K, Sakamoto K, Honda G, Kobayashi S, Endo I, Hasegawa K, Kotake K, Itabashi M, Hashiguchi Y, et al. Validation study of the JSHBPS nomogram for patients with colorectal liver metastases who underwent hepatic resection in the recent era - a nationwide survey in Japan. J Hepatobiliary Pancreat Sci. 2023;30:591–601.
doi: 10.1002/jhbp.1256
pubmed: 36285571
Berardi G, Chou J, Gonen M, Balachandran VP, Drebin J, Jarnagin WR, Kingham TP, Soares KC, Wei A, D’Angelica M. A model to Predict Treatment failure in patients undergoing upfront surgery for Resectable Colorectal Liver metastases. Ann Surg Oncol. 2023;30:2820–7.
doi: 10.1245/s10434-023-13113-2
pubmed: 36692613
pmcid: 10089972
Margonis GA, Sasaki K, Gholami S, Kim Y, Andreatos N, Rezaee N, Deshwar A, Buettner S, Allen PJ, Kingham TP, et al. Genetic and morphological evaluation (GAME) score for patients with colorectal liver metastases. Br J Surg. 2018;105:1210–20.
doi: 10.1002/bjs.10838
pubmed: 29691844
Brudvik KW, Jones RP, Giuliante F, Shindoh J, Passot G, Chung MH, Song J, Li L, Dagenborg VJ, Fretland Å, et al. RAS Mutation Clinical Risk score to Predict Survival after Resection of Colorectal Liver metastases. Ann Surg. 2019;269:120–6.
doi: 10.1097/SLA.0000000000002319
pubmed: 28549012
Takeda Y, Mise Y, Takahashi Y, Ito H, Inoue Y, Yoshioka R, Ono Y, Saiura A. Limited prognostic value of KRAS in patients undergoing Hepatectomy for Colorectal Liver metastases. Ann Surg Oncol. 2022;29:2383–91.
doi: 10.1245/s10434-021-11015-9
pubmed: 34851437
Vauthey JN, Zimmitti G, Kopetz SE, Shindoh J, Chen SS, Andreou A, Curley SA, Aloia TA, Maru DM. RAS mutation status predicts survival and patterns of recurrence in patients undergoing hepatectomy for colorectal liver metastases. Ann Surg. 2013;258:619–26. discussion 626 – 617.
doi: 10.1097/SLA.0b013e3182a5025a
pubmed: 24018645
Shindoh J, Nishioka Y, Yoshioka R, Sugawara T, Sakamoto Y, Hasegawa K, Hashimoto M, Kokudo N. KRAS Mutation Status predicts site-specific recurrence and survival after resection of colorectal liver metastases irrespective of location of the primary lesion. Ann Surg Oncol. 2016;23:1890–6.
doi: 10.1245/s10434-016-5087-5
pubmed: 26786089
Takamoto T, Sano K, Hashimoto T, Ichida A, Shimada K, Maruyama Y, Makuuchi M. Practical contribution of virtual Hepatectomy for Colorectal Liver metastases: a propensity-matched analysis of clinical outcome. J Gastrointest Surg. 2018;22:2037–44.
doi: 10.1007/s11605-018-3860-4
pubmed: 29980979
Oba M, Hasegawa K, Matsuyama Y, Shindoh J, Mise Y, Aoki T, Sakamoto Y, Sugawara Y, Makuuchi M, Kokudo N. Discrepancy between recurrence-free survival and overall survival in patients with resectable colorectal liver metastases: a potential surrogate endpoint for time to surgical failure. Ann Surg Oncol. 2014;21:1817–24.
doi: 10.1245/s10434-014-3504-1
pubmed: 24499828
Vakiani E, Janakiraman M, Shen R, Sinha R, Zeng Z, Shia J, Cercek A, Kemeny N, D’Angelica M, Viale A, et al. Comparative genomic analysis of primary versus metastatic colorectal carcinomas. J Clin Oncol. 2012;30:2956–62.
doi: 10.1200/JCO.2011.38.2994
pubmed: 22665543
pmcid: 3417049
Cervantes A, Adam R, Roselló S, Arnold D, Normanno N, Taïeb J, Seligmann J, De Baere T, Osterlund P, Yoshino T, et al. Metastatic colorectal cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up. Ann Oncol. 2023;34:10–32.
doi: 10.1016/j.annonc.2022.10.003
pubmed: 36307056
Höppener DJ, Nierop PMH, van Amerongen MJ, Olthof PB, Galjart B, van Gulik TM, de Wilt JHW, Grünhagen DJ, Rahbari NN, Verhoef C. The disease-free interval between resection of primary colorectal malignancy and the detection of hepatic metastases predicts Disease Recurrence but not overall survival. Ann Surg Oncol. 2019;26:2812–20.
doi: 10.1245/s10434-019-07481-x
pubmed: 31147988
pmcid: 6682566
Wensink GE, Bolhuis K, Elferink MAG, Fijneman RJA, Kranenburg O, Borel Rinkes IHM, Koopman M, Swijnenburg RJ, Vink GR, Hagendoorn J, et al. Predicting early extrahepatic recurrence after local treatment of colorectal liver metastases. Br J Surg. 2023;110:362–71.
doi: 10.1093/bjs/znac461
pubmed: 36655278
pmcid: 10364507
Okuno M, Goumard C, Kopetz S, Vega EA, Joechle K, Mizuno T, Omichi K, Tzeng CD, Chun YS, Vauthey JN, Conrad C. RAS Mutation is Associated with unsalvageable recurrence following Hepatectomy for Colorectal Cancer Liver metastases. Ann Surg Oncol. 2018;25:2457–66.
doi: 10.1245/s10434-018-6517-3
pubmed: 29786130
Zhang Q, Peng J, Ye M, Weng W, Tan C, Ni S, Huang D, Sheng W, Wang L. KRAS Mutation Predicted more mirometastases and closer resection margins in patients with colorectal Cancer Liver metastases. Ann Surg Oncol. 2020;27:1164–73.
doi: 10.1245/s10434-019-08065-5
pubmed: 31720935
Margonis GA, Kim Y, Spolverato G, Ejaz A, Gupta R, Cosgrove D, Anders R, Karagkounis G, Choti MA, Pawlik TM. Association between Specific Mutations in KRAS Codon 12 and colorectal liver metastasis. JAMA Surg. 2015;150:722–9.
doi: 10.1001/jamasurg.2015.0313
pubmed: 26038887
pmcid: 4696064
Margonis GA, Kim Y, Sasaki K, Samaha M, Amini N, Pawlik TM. Codon 13 KRAS mutation predicts patterns of recurrence in patients undergoing hepatectomy for colorectal liver metastases. Cancer. 2016;122:2698–707.
doi: 10.1002/cncr.30085
pubmed: 27244540
Margonis GA, Amini N, Andreatos N, Sasaki K, McVey J, Mirza MB, Warner S, Buettner S, Barbon C, Wang J, et al. KRAS mutational status impacts pathologic response to pre-hepatectomy chemotherapy: a study from the International Genetic Consortium for Liver Metastases. HPB (Oxford). 2019;21:1527–34.
doi: 10.1016/j.hpb.2019.03.368
pubmed: 30979646
Nishioka Y, Shindoh J, Yoshioka R, Gonoi W, Abe H, Okura N, Yoshida S, Sakamoto Y, Hasegawa K, Fukayama M, Kokudo N. Clinical impact of Preoperative Chemotherapy on Microscopic Cancer Spread surrounding colorectal liver metastases. Ann Surg Oncol. 2017;24:2326–33.
doi: 10.1245/s10434-017-5845-z
pubmed: 28349338
Nordlinger B, Sorbye H, Glimelius B, Poston GJ, Schlag PM, Rougier P, Bechstein WO, Primrose JN, Walpole ET, Finch-Jones M, et al. Perioperative chemotherapy with FOLFOX4 and surgery versus surgery alone for resectable liver metastases from colorectal cancer (EORTC Intergroup trial 40983): a randomised controlled trial. Lancet. 2008;371:1007–16.
doi: 10.1016/S0140-6736(08)60455-9
pubmed: 18358928
pmcid: 2277487
Nordlinger B, Sorbye H, Glimelius B, Poston GJ, Schlag PM, Rougier P, Bechstein WO, Primrose JN, Walpole ET, Finch-Jones M, et al. Perioperative FOLFOX4 chemotherapy and surgery versus surgery alone for resectable liver metastases from colorectal cancer (EORTC 40983): long-term results of a randomised, controlled, phase 3 trial. Lancet Oncol. 2013;14:1208–15.
doi: 10.1016/S1470-2045(13)70447-9
pubmed: 24120480
Benoist S, Nordlinger B. The role of preoperative chemotherapy in patients with resectable colorectal liver metastases. Ann Surg Oncol. 2009;16:2385–90.
doi: 10.1245/s10434-009-0492-7
pubmed: 19554377